Arcturus Therapeutics Holdings Inc is a biotechnology company focused on the development of transformative RNA medicines. The company utilizes its proprietary platform to create innovative therapies targeting various diseases, including infectious diseases and genetic disorders. By leveraging advanced technologies, such as self-amplifying mRNA and lipid nanoparticle delivery systems, Arcturus aims to improve the efficacy and safety of vaccines and therapeutics. Their pipeline includes candidates designed for both human and veterinary applications, reflecting their commitment to addressing significant unmet medical needs and enhancing patient outcomes. Read More
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced interim results from its ongoing Phase 2 clinical trial of ARCT-032, an investigational inhaled mRNA therapy for people with cystic fibrosis.
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Brera Holdings (NASDAQ: BREA), which is rebranding as Solmate and pivoting to a Solana-based digital asset treasury and crypto infrastructure, surged after Cathie Wood’s ARK Invest purchased 6,500,001 shares valued at about $49.72 million on Sept. 18 through ARKK, ARKW and ARKF funds. The move follows Brera’s $300 million oversubscribed private placement backed by Pulsar Group, RockawayX and ARK. Meanwhile, ARK sold 47,474 Roku (NASDAQ: ROKU) shares for roughly $4.67 million and trimmed 43,157 Tempus AI (TEM) shares for $3.73 million, while adding positions in Arcturus Therapeutics (NASDAQ: ARCT), ATAI Life Sciences (NASDAQ: ATAI), AeroVironment (NASDAQ: AVAV), Baidu (NASDAQ: BIDU) and Pony.ai (NASDAQ: PONY). BREA stock is up more than 200% year to date.
On Thursday, Cathie Wood-led Ark Invest executed significant trades, notably selling shares of Tempus AI Inc (NASDAQ:TEM) and buying shares of Brera Holdings PLC (NASDAQ:BREA),
NetworkNewsWire Editorial Coverage : Innovation in RNA-based, immunotherapy and targeted therapeutics is not just aspirational, it’s urgently needed. Aggressive cancers such as glioblastoma and pancreatic cancer remain devastatingly lethal, while pediatric rare diseases continue to claim too many young lives each year. In this landscape of unmet medical need, Oncotelic Therapeutics Inc. (OTCQB: OTLC) ( Profile ) stands out. Under the visionary leadership of chair and CEO Dr. Vuong Trieu, the company is leveraging AI, nanomedicine and novel clinical models to reshape biotech. With a robust IP backbone, bolstered by more than 500 patent applications and 75 issued patents, Oncotelic is building a breakthrough portfolio aimed at transforming cancer and rare disease treatment. The company is joining other leading innovators in the cancer and rare disease treatment space, including IO Biotech Inc. (NASDAQ: IOBT), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Autolus Therapeutics PLC (NASDAQ: AUTL) and…
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that the Company will participate in the following investor conferences:
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced its financial results for the second quarter ended June 30, 2025, and provided corporate updates.
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended June 30, 2025 after the market close on Monday, August 11 and will also host a conference call and webcast at 4:30 pm Eastern Time on August 11, 2025.
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences:
